ClinicalTrials.gg
CompletedNCT01821066Updated Oct 8, 2015

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

A Phase 1 interventional study of PD-0332991 alone and Tamoxifen 60 mg in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-08.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of PD-0332991 in healthy male volunteers.

02

Conditions studied

  • Healthy

Keywords

  • PD-0332991
  • palbociclib
  • tamoxifen
  • drug-drug interaction (DDI) study
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male between the ages of 18 and 55 years of age inclusive
  • (BMI) between 17.5 and 30.5 kg/m2
  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • a positive urine drug screen
  • a supine systolic blood pressure >140 mm Hg, or diastolic blood pressure >90 mm H.
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Two-Period Fixed-Sequence Arm

    This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.

    Drug: PD-0332991 alone · Drug: Tamoxifen 60 mg · Drug: Tamoxifen 20 mg · Drug: PD-0332991 combination

Interventions

  • PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.

    Also known as: PD-0332991, palbociclib

  • On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).

  • On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.

  • DrugPD-0332991 combination

    Drug page: Palbociclib

    PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.

    Also known as: PD-0332991, palbociclib

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PD-0332991

    AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).

    Time frame: 0-144 hrs post PD-0332991 dose

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PD-0332991

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: 0-144 hrs post PD-0332991 dose

  2. Maximum Observed Plasma Concentration (Cmax) of PD-0332991

    Time frame: 0-144 hrs post PD-0332991 dose

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991

    Time frame: 0-144 hrs post PD-0332991 dose

  4. Plasma Decay Half-Life (t1/2) of PD-0332991

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0-144 hrs post PD-0332991 dose

  5. Apparent Oral Clearance (CL/F) of PD-0332991

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 0-144 hrs post PD-0332991 dose

  6. Apparent Volume of Distribution (Vz/F) of PD-0332991

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 0-144 hrs post PD-0332991 dose

  7. Minimum Observed Plasma Trough Concentration (Cmin) of tamoxifen

    Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2

  8. Minimum Observed Plasma Trough Concentration (Cmin) of 4-hydroxytamoxifen

    Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2

  9. Minimum Observed Plasma Trough Concentration (Cmin) of N-desmethyltamoxifen

    Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2

  10. Minimum Observed Plasma Trough Concentration (Cmin) of endoxifen

    Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2

07

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2013
First posted
Mar 29, 2013
Start
Apr 2013
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Last update
Oct 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01821066
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 29, 2013
Start date
Apr 2013
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Oct 8, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion